✨ Free AI Report
Cabaletta Bio, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Cabaletta Bio, Inc.
Research Preview

Cabaletta Bio, Inc.: Business Overview, Financials & Competitive Analysis

Cabaletta Bio is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The company applies i...

Analyst-debate audio for Cabaletta Bio, Inc.

AskCyborg analysts argue the bull and bear cases for Cabaletta Bio, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Cabaletta Bio, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
7/ 10Strong

Cyborg Score thesis

Pioneer in curative CD19-CAR T therapies for autoimmune diseases with late-stage clinical momentum and clear regulatory pathway,...

Read the full analyst-debate transcript →
Industry Biotechnology - Cell & Gene Therapy
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Cabaletta Bio, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Cabaletta Bio, Inc. Overview

Pro stress-test →

Cabaletta Bio is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The company applies its CABA platform to develop T cell therapies to transform the lives of patients with autoimmune diseases by aiming to deliver deep and durable – potentially curative – responses.

Strategic Profile

Pro stress-test →

The CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) with CABA-201, a 4-1BB-containing fully human CD19-CAR T as lead candidate, and CAART (chimeric autoantibody receptor T cells) with multiple clinical-stage candidates. The company has initiated enrollment in its first pivotal program in myositis and expects the study could support a biologics license application (BLA) filing next year.

Competitive Landscape

Pro stress-test →

Cabaletta competes in the CD19-CAR T space for autoimmunity, a nascent market where competitors include Allogene Therapeutics and Century Therapeutics pursuing similar approaches. Building on established success of T cell therapies in cancer and recent compelling clinical data on CD19-CAR T in autoimmunity, Cabaletta is developing CARTA to address a broad range of autoimmune diseases. Differentiation lies in disease specificity (autoimmunity vs. oncology heritage) and multi-indication platform scope.

Industry Context

Cabaletta Bio, Inc. operates in Biotechnology - Cell & Gene Therapy.

Key facts

Founded: 2017 · Headquarters: Philadelphia, PA

What the analysts stress-tested

The top findings that survived the multi-agent debate for Cabaletta Bio, Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Cabaletta Bio, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Cellular ImmunotherapiesAllogeneic CAR T cell therapies→CD19-CAR T ProgramsUniversal CAR T cell therapies→Engineered Cell TherapiesCAR T and cell therapy programs→

Compare Cabaletta Bio, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Cabaletta Bio, Inc. operates in Biotechnology - Cell & Gene Therapy. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Cell & Gene Therapy research →
NEW · MCP server

Ask your AI assistant about Cabaletta Bio, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Cabaletta Bio, Inc. and its top competitor on Cyborg Score”
“What did Cabaletta Bio, Inc. do this quarter?”
“Is Cabaletta Bio, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Cabaletta Bio, Inc. do?+
Cabaletta Bio is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The company applies i...
What is Cabaletta Bio, Inc.'s Cyborg Score?+
Cabaletta Bio, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Cabaletta Bio, Inc.'s main competitors?+
Named competitors include Cellular Immunotherapies, CD19-CAR T Programs, Engineered Cell Therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Cabaletta Bio, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Cabaletta Bio, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Cabaletta Bio, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology - Cell & Gene Therapy research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Sana Biotechnology, Inc.5Adicet Bio, Inc.4BrainStorm Cell Therapeutics Inc.